AstraZeneca lung cancer drug given green light in US

FDA approval of Tagrisso offers major boost for British company, seeking to release six new cancer medicines by 2020A new lung cancer pill from AstraZeneca has been approved by US regulators, in a major boost for the British drugmaker.AZD9291, which will be sold as Tagrisso, is for advanced non-small-cell lung cancer, the most common form of lung cancer. Tagrisso targets a genetic mutation, known as T790M, that helps tumours evade current lung cancer pills. The drug will be made available to patients in the US as soon as possible and its price will be “comparable to other oral cancer therapies,” a spokeswoman said. AstraZeneca will reveal the price early next week. Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: AstraZeneca Business Pharmaceuticals industry Cancer Health Society Medical research Source Type: news

Related Links:

Authors: Kara HV, Karaaltin AB, Ersen E, Alaskarov E, Kilic B, Turna A Abstract Introduction: Video-assisted mediastinal lymphadenectomy (VAMLA) is a valuable tool for invasive staging of the mediastinum. Unilateral vocal cord paralysis (UVCP) may occur in patients following VAMLA and may result in secretion retention within the lungs, atelectasis and associated infectious situations such as pneumonia. Minimally invasive injection laryngoplasty (ILP) is the treatment of choice in UVCP. Aim: To evaluate the efficacy and success of acute minimally invasive injection laryngoplasty for patients with UVCP following ...
Source: Videosurgery and Other Miniinvasive Techniques - Category: Surgery Tags: Wideochir Inne Tech Maloinwazyjne Source Type: research
Publication date: November 2018Source: Pharmacological Research, Volume 137Author(s): Wenlong Li, Rolf W. Sparidans, Yaogeng Wang, Maria C. Lebre, Jos H. Beijnen, Alfred H. SchinkelAbstractBrigatinib is an FDA-approved oral anaplastic lymphoma kinase (ALK) inhibitor for treatment of metastatic non-small cell lung cancer (NSCLC). Using genetically modified mouse models, we investigated the roles of the multidrug efflux transporters ABCB1 and ABCG2, and the multispecific drug-metabolizing enzyme CYP3 A in plasma pharmacokinetics and tissue distribution of brigatinib. In vitro, brigatinib was exceptionally well transpo...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
This study sought to investigate the inhibitory effects of An-te-xiao capsule on three main types of NSCLC cell lines (A549, NCI-H460, and NCI-H520) in vitro and in vivo and the underlying mechanisms of action including its potential anti-angiogenesis effects. An-te-xiao capsule showed no acute oral toxicity in mice, and significantly prolonged survival time in a mouse model of Lewis tumor xenograft. The inhibition of A549, NCI-H460, and NCI-H520 cells by An-te-xiao capsule was reflected in its effects on tumor growth, histopathological changes, tumor microvessel density (MVD), cell cycle regulatory proteins, and cell apop...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Conclusions OMV produced non-negligible survival in patients and also showed stable long-term blood concentrations. The schedule of 20 –30 mg every other day without interruption gave good tolerability and clinical benefit.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
Abstract The targeted treatment of advanced non-small cell lung cancer (NSCLC) harboring genomic rearrangement of ALK is a paradigm for personalized oncology. More than 15 different ALK fusion partners have been discovered in NSCLC patients. Most of these ALK fusions responded well to the ALK inhibitor crizotinib. Crizotinib is an oral MET/ALK inhibitor used as first-line therapy in the treatment of advanced NSCLC harboring ALK rearrangement. An understanding of the mechanisms by which tumors harbor primary drug resistance or acquired resistance to targeted therapies is critical for predicting which patients will ...
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
Abstract BACKGROUND: Afatinib is an oral, irreversible ErbB family blocker indicated for first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with non-resistant epidermal growth factor receptor (EGFR) mutations. Afatinib is also approved for the treatment of metastatic squamous NSCLC following progression on platinum-based chemotherapy. Common afatinib-associated toxicities include gastrointestinal and dermatologic events, which can be dose limiting. OBJECTIVES: In this review, the authors describe clinical trial experiences with afatinib, as well as best practices and practical a...
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research
Authors: Kashiwabara K, Semba H, Fujii S, Tsumura S Abstract It is not clear whether sequential chemotherapy can be performed immediately in patients with p-stage I non-small cell lung cancer recurring during a 2-year period of daily oral administration with tegafur-uracil (UFT) as postoperative adjuvant chemotherapy. Patients receiving chemotherapy within 1 month after the discontinuation of UFT (n = 10) (five cases with aggressive recurrent tumors) had the increased risk of grade 4 neutropenia, but the overall survival was not inferior to that in patients who received chemotherapy beginning more tha...
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
This study sought to develop a simple and sensitive competitive enzyme-linked immunosorbent assay (ELISA) to quantify afatinib in plasma for routine pharmacokinetic applications. An anti-afatinib antibody was obtained using (S)-N-4-(3-chloro-4-fluorophenyl)-7-(tetrahydrofuran-3-yloxy)-quinazoline-4,6-diamine (CTQD), which has the same substructure as afatinib, as a hapten. Enzyme labeling of afatinib with horseradish peroxidase was similarly performed using CTQD. A simple competitive ELISA for afatinib was developed based on the principle of direct competition between afatinib and the enzyme marker for the anti-afatinib an...
Source: Journal of Pharmaceutical Analysis - Category: Drugs & Pharmacology Source Type: research
Condition:   Local Advanced Non-small Cell Lung Cancer Interventions:   Dietary Supplement: ONS from the start of radiotherapy;   Dietary Supplement: ONS from the time of grade 2 radiation esophagitis;   Dietary Supplement: Energy goal-based ONS;   Dietary Supplement: Prealbumin goal-based ONS;   Radiation: Thoracic radiotherapy;   Drug: Weekly DP che motherapy concurrent with thoracic radiotherapy Sponsor:   Sun Yat-sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion Ammonium sulfate gradient method can be successfully applied to prepare afatinib liposomes that performed higher encapsulation efficiency and smaller particle size. The UV spectrophotometry employed to determine the liposome encapsulation efficiency was easy operation and with high accuracy. 
 DOI: 10.3779/j.issn.1009-3419.2018.09.02
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
More News: AstraZeneca | Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Health | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Research | Science